Dr Chengbin Wu, founder and CEO of EpimAb Biotherapeutics, introduces their exciting and proprietary bispecific antibody-generating platform, Fabs-In-Tandem Immunoglobulin (FIT-Ig®) and its ability to discover and generate novel and differentiated bispecific antibodies to meet unmet medical needs in China; shares the progress of their first program, EMB01, a EGFR-cMet bispecific antibody that just started its Phase I/II trial in February 2019; and gives his perspective on the importance of discipline to an early-stage biotech CEO.
The local Chinese industry has a history of working with generics and biosimilars, which is a matter of ‘reverse-engineering’. We are working to change this focus by utilizing our FIT-Ig platform to develop novel therapeutics
